D003092DisordersC06.405.205.265C06.405.469.158.1881893360.77071Colitisplugins:FeaturedVideosFeatured VideosFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:pluginSearchableDataProfilesRNS Plugin Searchable Dataprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentDivisionvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonMelanoma Medical OncologyMD AndersonADIDIABADI DIAB9901DIAB, ADIAssistant Professor74Professor10Assistant Professor2Adjunct Assistant Professortrue1ProfessorProfessor4.47280.00558897189research area of0.9892410.0147575183subject area forDepartment of PediatricsDepartment of Molecular Virology & MicrobiologyDepartment of Pathology & ImmunologyMolecular Virology & MicrobiologyPathologyPediatrics-GastroenterologyBaylor College of MedicineRICHARDKELLERMAYERRICHARD KELLERMAYER29.70508570000000-95.401808700000001082KELLERMAYER, RICHARDProfessorJAMESVERSALOVICJAMES VERSALOVIC0.000000000000000.000000000000003197VERSALOVIC, JAMESProfessorTORSAVIDGETOR SAVIDGE0.000000000000000.000000000000004547SAVIDGE, TORProfessortrue1ProfessorProfessortrue1ProfessorProfessor37031740Liu Y, Ahumada AL, Bayraktar E, Schwartz P, Chowdhury M, Shi S, Sebastian MM, Khant H, de Val N, Bayram NN, Zhang G, Vu TC, Jie Z, Jennings NB, Rodriguez-Aguayo C, Swain J, Stur E, Mangala LS, Wu Y, Nagaraju S, Ermias B, Li C, Lopez-Berestein G, Braam J, Sood AKJournal of controlled release : official journal of the Controlled Release SocietyEnhancing oral delivery of plant-derived vesicles for colitis. J Control Release. 2023 05; 357:472-483.J Control Release2023-04-20T00:00:002023Enhancing oral delivery of plant-derived vesicles for colitis.37315113Halsey TM, Thomas AS, Hayase T, Ma W, Abu-Sbeih H, Sun B, Parra ER, Jiang ZD, DuPont HL, Sanchez C, El-Himri R, Brown A, Flores I, McDaniel L, Ortega Turrubiates M, Hensel M, Pham D, Watowich SS, Hayase E, Chang CC, Jenq RR, Wang YScience translational medicineMicrobiome alteration via fecal microbiota transplantation is effective for refractory immune checkpoint inhibitor-induced colitis. Sci Transl Med. 2023 06 14; 15(700):eabq4006.Sci Transl Med2023-06-14T00:00:002023Microbiome alteration via fecal microbiota transplantation is effective for refractory immune checkpoint inhibitor-induced colitis. The microbiome and fecal microbiota transplantation37721546Magahis PT, Satish D, Esther Babady N, Kamboj M, Postow MA, Laszkowska M, Faleck DMThe oncologistPrevalence of Enteric Infections in Patients on Immune Checkpoint Inhibitors and Impact on Management and Outcomes. Oncologist. 2024 Jan 05; 29(1):36-46.Oncologist2024-01-05T00:00:002024Prevalence of Enteric Infections in Patients on Immune Checkpoint Inhibitors and Impact on Management and Outcomes.true1Adjunct Assistant ProfessorAdjunct Assistant Professor37984469Venken K, Decruy T, Sparwasser T, Elewaut DImmunologyTregs protect against invariant NKT cell-mediated autoimmune colitis and hepatitis. Immunology. 2024 Feb; 171(2):277-285.Immunology2023-11-20T00:00:002023Tregs protect against invariant NKT cell-mediated autoimmune colitis and hepatitis.38296594Harvey C, Nahar KJ, McKeown J, Lo SN, Farag S, Yousaf N, Young K, Tas L, Meerveld-Eggink A, Blank C, Thomas A, McQuade J, Schilling B, Johnson DB, Huertas RM, Arance A, Lee J, Zimmer L, Long GV, Carlino MS, Wang Y, Menzies AMJournal for immunotherapy of cancerManagement of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series. J Immunother Cancer. 2024 01 31; 12(1).J Immunother Cancer2024-01-31T00:00:002024Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series.true1Assistant ProfessorAssistant ProfessorGRETCHENDIEHLGRETCHEN DIEHL7919DIEHL, GRETCHENAdjunct Assistant Professor